NCT00653835已完成4 期
SCH 58235: A Multicenter, Randomised, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, and Tolerability Of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg vs Ezetimibe Placebo With Simvastatin 20 mg in Untreated Subjects With Primary Hypercholesterolaemia And Coronary Heart Disease (Protocol P03435)
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 153
- 主要终点
- Percent change in LDL-C from baseline to endpoint.
研究概览
简要总结
This study will assess whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be more effective than treatment with simvastatin 20 mg alone in reducing LDL-C concentrations when administered for 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>=18 years and <= 75 years of age
- •LDL-C concentration >= 3.3 mmol/L (130 mg/dL) to <= 4.9 mmol/L (190 mg/dL) at baseline.
- •Triglyceride concentration <3.99 mmol/L (350 mg/dL) at baseline.
- •Documented coronary heart disease (CHD), which will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing); history of MI; history of PCI (primarily PTCA with or without stent replacement); symptomatic peripheral vascular disease; documented history of atherothrombotic cerebrovascular disease; and/or documented history of non-Q wave MI.
- •Stable weight history for at least 4 weeks prior to entry into study at baseline.
- •Female subjects of childbearing potential must be using an acceptable method of birth control or be surgically sterilized.
排除标准
- •Body mass index (BMI) >=35 kg/m^2 at baseline.
- •Subjects whose liver transaminases (ALT, AST) are >1.5 times the upper limit of normal and with active liver diseases at baseline.
- •Subjects with evidence of current myopathy (including subjects with CK>1.5 times above the upper limit of normal) at baseline.
- •Subjects with clinical laboratory tests (CBC, blood chemistries, urinalysis) outside the normal range that are clinically acceptable to the investigator at baseline.
- •Subjects with Type II diabetes mellitus who are poorly controlled (HbA1c>9%) or newly diagnosed (within 3 months) or who have had a change in anti-diabetic therapy within 3 months of baseline.
- •Subjects with Type I diabetes mellitus who have not been on a stable insulin regimen for 3 months prior to baseline, or who have a recent history of repeated hypoglycaemia or unstable glycaemic control.
- •Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.
- •Female subjects who consume >14 units and male subjects who consume >21 units of alcohol per week.
- •Female subjects who are pregnant or breast feeding.
- •Subjects who have not observed the designated washout periods for any of the prohibited medications.
研究组 & 干预措施
Ezetimibe + Simvastatin
Experimental
干预措施: Ezetimibe + Simvastatin (Drug)
Simvastatin
Active Comparator
干预措施: Simvastatin (Drug)
结局指标
主要结局
Percent change in LDL-C from baseline to endpoint.
时间窗: 6 weeks
次要结局
- Percent of subjects who achieve LDL-C ESC goal (ie, <3 mmol/L [115 mg/dL]) at endpoint.(6 weeks)
- Percent change from baseline to endpoint in total cholesterol, HDL-C and triglycerides.(6 weeks)
- Safety: adverse events, laboratory test results, vital signs.(Throughout study)
研究者
相似试验
已完成
4 期
Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)AtherosclerosisHypercholesterolemiaNCT00653796Organon and Co148
终止
3 期
Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)AtherosclerosisHypercholesterolemiaNCT00651391Organon and Co28
已完成
4 期
The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin StudyMetabolic SyndromeNCT00817843dr.Frank L.J. Visseren100
已完成
3 期
A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)Coronary DiseaseNCT00551447Organon and Co616
终止
4 期
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)AtherosclerosisHypercholesterolemiaCoronary Artery DiseaseNCT00651378Organon and Co87